RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo

By Beata Urban-Klein, S. Werth, Shaker Abuharbeid, F. Czubayko, A. Aigner. Gene Therapy, 2005

735 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Breaking down the barriers: siRNA delivery and endosome escape (2010, background): “Polyethyleneimine (PEI) is one of the most widely used cationic polymers for nucleic acid delivery (Read et al., 2005; Richards Grayson et al., 2006; Urban-Klein et al., 2005).”
Nanocarriers’ entry into the cell: relevance to drug delivery (2009, methodology): “In vivo, these polyplexes also displayed antitumoral activity after subcutaneous or intraperitoneal administration, as shown with a siRNA targeted against the growth factor pleiotrophin [185] and the HER-2 receptor [186] in murine subcutaneous tumor models.”
Innovative approaches for cancer treatment: current perspectives and new challenges (2019, background): “PEI is able to form small cationic nanoparticles containing siRNAs and it has been exploited as antitumoural, upon loading with HER-2 receptor-specific siRNA [201].”
siRNA delivery systems for cancer treatment. (2009, background): “PEI-complexed siRNA, but not free siRNA, resulted in a marked reduction in tumor growth through siRNAmediated HER-2 downregulation in the animal model [111].”
RNAi therapeutics: a potential new class of pharmaceutical drugs (2006, background): “Simpler PEI formulations have also shown efficacy in xenograft tumor models 79 , as have complexes of siRNA duplexes with atelocollagen.”